The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The disclosure is directed to compounds of Formula I ##STR00001##
Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

The disclosure is directed to compounds of Formula I ##STR00001##
Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.

Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I):

##STR00001##

wherein R.sup.1 is a moiety including a positron emitter; R.sup.2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R.sup.1 is a moiety including an adamantyl group.